Royal Bank of Canada Boosts Health Catalyst (NASDAQ:HCAT) Price Target to $9.00

Health Catalyst (NASDAQ:HCAT) had its price target hoisted by investment analysts at Royal Bank of Canada from $8.00 to $9.00 in a report released on Thursday,Benzinga reports. The firm presently has a “sector perform” rating on the stock. Royal Bank of Canada’s target price would indicate a potential upside of 9.22% from the company’s previous close.

A number of other brokerages have also commented on HCAT. Piper Sandler lowered their target price on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating on the stock in a research note on Monday, August 26th. Evercore ISI boosted their target price on Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research note on Tuesday, October 8th. JPMorgan Chase & Co. boosted their target price on Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a research note on Wednesday, September 4th. Stephens decreased their price objective on Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $16.00 price objective on shares of Health Catalyst in a research note on Friday, October 4th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $11.64.

Health Catalyst Stock Down 7.0 %

Shares of Health Catalyst stock traded down $0.62 on Thursday, hitting $8.24. 674,743 shares of the company’s stock traded hands, compared to its average volume of 485,899. Health Catalyst has a one year low of $5.42 and a one year high of $11.41. The company has a fifty day moving average of $8.07 and a two-hundred day moving average of $7.14.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.49%. The firm had revenue of $76.40 million during the quarter, compared to analyst estimates of $76.27 million. During the same period last year, the business posted ($0.22) EPS. The company’s revenue was up 3.5% on a year-over-year basis. Equities research analysts anticipate that Health Catalyst will post -0.35 EPS for the current year.

Insider Activity

In related news, COO Daniel Lesueur sold 5,209 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $7.70, for a total value of $40,109.30. Following the sale, the chief operating officer now owns 129,690 shares in the company, valued at $998,613. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, insider Kevin Lee Freeman sold 7,500 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total value of $54,150.00. Following the transaction, the insider now directly owns 255,881 shares in the company, valued at $1,847,460.82. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, COO Daniel Lesueur sold 5,209 shares of the firm’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $7.70, for a total value of $40,109.30. Following the completion of the transaction, the chief operating officer now directly owns 129,690 shares in the company, valued at approximately $998,613. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 35,396 shares of company stock valued at $266,280. Insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. First Light Asset Management LLC grew its position in Health Catalyst by 438.5% in the second quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock worth $25,279,000 after acquiring an additional 3,221,408 shares in the last quarter. Impax Asset Management Group plc grew its position in Health Catalyst by 16.4% in the third quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company’s stock worth $20,793,000 after acquiring an additional 360,201 shares in the last quarter. Millennium Management LLC grew its position in Health Catalyst by 96.3% in the second quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock worth $15,421,000 after acquiring an additional 1,184,131 shares in the last quarter. Primecap Management Co. CA grew its position in Health Catalyst by 1.1% in the third quarter. Primecap Management Co. CA now owns 2,404,462 shares of the company’s stock worth $19,572,000 after acquiring an additional 25,000 shares in the last quarter. Finally, Daventry Group LP grew its position in Health Catalyst by 3.9% in the second quarter. Daventry Group LP now owns 2,247,053 shares of the company’s stock worth $14,359,000 after acquiring an additional 84,178 shares in the last quarter. Hedge funds and other institutional investors own 85.00% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.